Shield is a DNA blood test and therefore not suitable for mass population screening (too expensive).
The article states in the first paragraph that Guardant are keenly investing in possibly ways to raise compliance among test resistant people.
You provide more evidence that the global race to find a way to increase colorectal cancer screening is huge. There is a lot of money to be made, and Rhythm's Colostat is winning!
RHY Price at posting:
95.0¢ Sentiment: Buy Disclosure: Held
